Why Medtronic Stock Marched Higher on Monday
(NYSE: MDT) stock was a fairly hot item as the trading week kicked off, with investors pushing the shares up by almost 3% in value. They liked the medical device specialist's latest piece of news about one of its products, and reacted accordingly. The stock's gain easily topped that of the S 500 (SNPINDEX: ^GSPC), which closed the day up 0.6%.
On Sunday, Medtronic published five-year data from a low-risk clinical trial of its Evolut transcatheter aortic valve replacement (TAVR) system.
In the trial, TAVR, which assists patients suffering from the heart valve disorder aortic stenosis, was tested against surgical aortic vale replacement (SAVR). The trial's participants all had severe forms of the disorder. TAVR was shown to have comparable rates of all-cause mortality or disabling stroke.
Source Fool.com
Medtronic plc Stock
Medtronic plc is currently one of the favorites of our community with 18 Buy predictions and no Sell predictions.
With a target price of 94 € there is a slightly positive potential of 17.25% for Medtronic plc compared to the current price of 80.17 €.
